tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Argenx initiated with an Outperform at RBC Capital

RBC Capital analyst Luca Issi initiated coverage of Argenx (ARGX) with an Outperform rating and $850 price target The firm’s doctor checks suggest Vyvgart uptake is likely to accelerate from here given continued execution in approved indications and more convenient dosing. Argenx is a rare biotech company with $2B in sales that may quadruple by the end of the decade, result in $10B in cumulative operating cash flows, the analyst tells investors in a research note.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1